down arrow

Avanos Medical, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05350V1061
USD
11.92
0.25 (2.14%)

Dec 18

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.6711.99

52 Week

9.3017.69
Valuation
Technical
Day's Volume

CASH

455.05 k

Shareholding (Mar 2025)

FII

6.42%

Held by 96 FIIs

DII

40.81%

Held by 60 DIIs

Promoter

0.06%

How big is Avanos Medical, Inc.?

22-Jun-2025

As of Jun 18, Avanos Medical, Inc. has a market capitalization of 564.21 million and reported net sales of 689.20 million, with a net profit loss of 380.20 million over the latest four quarters. Shareholder's funds are at 828.50 million, and total assets amount to 1,154.20 million.

As of Jun 18, Avanos Medical, Inc. has a market capitalization of 564.21 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 689.20 million for the latest four quarters. However, it also experienced a net profit loss of 380.20 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 828.50 million and total assets at 1,154.20 million.

Read More

What does Avanos Medical, Inc. do?

22-Jun-2025

Avanos Medical, Inc. is a medical technology company specializing in surgical and interventional pain management, as well as respiratory and digestive health. As of March 2025, it reported net sales of $168 million and a market cap of $564.21 million.

Overview: <BR>Avanos Medical, Inc. is a medical technology company that provides a portfolio of product offerings focused on surgical and interventional pain management, respiratory and digestive health, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 168 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 564.21 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.02 <BR>Return on Equity: 7.63% <BR>Price to Book: 0.67<BR><BR>Contact Details: <BR>Address: 5405 Windward Parkway, ALPHARETTA GA : 30004 <BR>Tel: 1 678 4259273 <BR>Website: https://avanos.com/

Read More

Who are in the management team of Avanos Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Avanos Medical, Inc. includes Chairman Gary Blackford, CEO Joseph Woody, and several independent directors: John Byrnes, William Hawkins, Heidi Kunz, Patrick O'Leary, and Maria Sainz. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Avanos Medical, Inc. includes the following individuals:<BR><BR>- Mr. Gary Blackford, Chairman of the Board<BR>- Mr. Joseph Woody, Chief Executive Officer and Director<BR>- Mr. John Byrnes, Independent Director<BR>- Mr. William Hawkins, Independent Director<BR>- Ms. Heidi Kunz, Independent Director<BR>- Mr. Patrick O'Leary, Independent Director<BR>- Ms. Maria Sainz, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is Avanos Medical, Inc. overvalued or undervalued?

20-Sep-2025

As of February 26, 2025, Avanos Medical, Inc. is considered a risky investment due to its overvaluation, reflected in a P/E ratio of 9, an EV to EBITDA of 6.23, and a significant underperformance of -49.28% over the past year compared to the S&P 500's 17.14% return.

As of 26 February 2025, the valuation grade for Avanos Medical, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued based on its current metrics, with a P/E ratio of 9, an EV to EBITDA of 6.23, and a PEG ratio of 0.12, which suggests that despite a low valuation in terms of earnings, the growth prospects may not justify the current price. <BR><BR>In comparison to peers, Avanos Medical's P/E ratio of 9.80 is higher than that of Paragon 28, Inc. at -20.38, but lower than Myriad Genetics, Inc. at -11.75, indicating that while it is relatively better positioned, the overall industry sentiment remains negative. The company's stock has underperformed significantly against the S&P 500, with a 1-year return of -49.28% compared to the index's 17.14%, reinforcing the notion of overvaluation amidst a challenging market environment.

Read More

Is Avanos Medical, Inc. technically bullish or bearish?

30-Sep-2025

As of September 26, 2025, Avanos Medical, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -26.07% versus 12.96% for the index.

As of 26 September 2025, the technical trend for Avanos Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the weekly Dow Theory, both indicating a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe, but is bearish on the monthly, while the RSI is bullish monthly but has no signal weekly. Bollinger Bands are bearish on both weekly and monthly timeframes. <BR><BR>In terms of performance, Avanos has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -26.07% compared to the S&P 500's 12.96%, and a one-year return of -49.89% versus 15.64% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 5.39%

  • The company has been able to generate a Return on Capital Employed (avg) of 5.39% signifying low profitability per unit of total capital (equity and debt)
2

Poor long term growth as Net Sales has grown by an annual rate of -0.37% over the last 5 years

 
3

Flat results in Jun 25

4

Risky -

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 580 Million (Micro Cap)

stock-summary
P/E

9.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.03

stock-summary
Return on Equity

7.62%

stock-summary
Price to Book

0.75

Revenue and Profits:
Net Sales:
175 Million
(Quarterly Results - Jun 2025)
Net Profit:
-77 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.93%
0%
-2.93%
6 Months
-1.32%
0%
-1.32%
1 Year
-26.33%
0%
-26.33%
2 Years
-44.99%
0%
-44.99%
3 Years
-54.28%
0%
-54.28%
4 Years
-62.21%
0%
-62.21%
5 Years
-75.17%
0%
-75.17%

Avanos Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Avanos Medical Experiences Evaluation Revision Amidst Mixed Market Performance Indicators

Avanos Medical Experiences Evaluation Revision Amidst Mixed Market Performance Indicators

Avanos Medical, Inc. has recently revised its evaluation amid fluctuating stock performance, closing at $11.55. The company has faced significant challenges, with a nearly 50% decline over the past year compared to the S&P 500's gains. Various technical indicators show mixed trends, reflecting ongoing market dynamics.

Read More

Is Avanos Medical, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Avanos Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Dow Theory also reflecting a mildly bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but remains bearish on the monthly. The RSI is bullish on the monthly but shows no signal on the weekly, suggesting mixed signals across different timeframes. In terms of performance, the stock has underperformed significantly against the S&P 500, with a year-to-date return of -26.07% compared to the S&P's 12.96%, and a one-year return of -49.89% versus the S&P's 15.64%....

Read More

Is Avanos Medical, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Avanos Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the weekly Dow Theory both indicating a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, while the RSI is bullish monthly but has no signal weekly. Additionally, Bollinger Bands are bearish for both weekly and monthly periods. In terms of performance, Avanos has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -26.07% versus the S&P 500's 12.96%, and a one-year return of -49.89% compared to 15.64% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.37%
EBIT Growth (5y)
-0.32%
EBIT to Interest (avg)
7.55
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.57
Tax Ratio
3.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
5.39%
ROE (avg)
4.86%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.69
EV to EBIT
11.40
EV to EBITDA
6.23
EV to Capital Employed
0.70
EV to Sales
0.87
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
6.11%
ROE (Latest)
7.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 74 Schemes (52.61%)

Foreign Institutions

Held by 96 Foreign Institutions (6.42%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.48% vs -6.74% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1,263.64% vs 101.66% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "175.00",
          "val2": "167.50",
          "chgp": "4.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "17.30",
          "val2": "16.90",
          "chgp": "2.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.10",
          "chgp": "-4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-81.50",
          "val2": "1.40",
          "chgp": "-5,921.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-76.80",
          "val2": "6.60",
          "chgp": "-1,263.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "41.70%",
          "val2": "43.60%",
          "chgp": "-0.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.15% vs -1.58% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3,802.02% vs -146.05% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "687.80",
          "val2": "673.30",
          "chgp": "2.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "85.50",
          "val2": "108.50",
          "chgp": "-21.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.20",
          "val2": "15.00",
          "chgp": "-18.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-440.10",
          "val2": "-47.50",
          "chgp": "-826.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-386.30",
          "val2": "-9.90",
          "chgp": "-3,802.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "58.20%",
          "val2": "96.50%",
          "chgp": "-3.83%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
175.00
167.50
4.48%
Operating Profit (PBDIT) excl Other Income
17.30
16.90
2.37%
Interest
2.00
2.10
-4.76%
Exceptional Items
-81.50
1.40
-5,921.43%
Consolidate Net Profit
-76.80
6.60
-1,263.64%
Operating Profit Margin (Excl OI)
41.70%
43.60%
-0.19%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.48% vs -6.74% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -1,263.64% vs 101.66% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
687.80
673.30
2.15%
Operating Profit (PBDIT) excl Other Income
85.50
108.50
-21.20%
Interest
12.20
15.00
-18.67%
Exceptional Items
-440.10
-47.50
-826.53%
Consolidate Net Profit
-386.30
-9.90
-3,802.02%
Operating Profit Margin (Excl OI)
58.20%
96.50%
-3.83%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 2.15% vs -1.58% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -3,802.02% vs -146.05% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Avanos Medical, Inc. stock-summary
stock-summary
Avanos Medical, Inc.
Pharmaceuticals & Biotechnology
Avanos Medical, Inc., formerly Halyard Health, Inc., is a medical technology company. The Company provides a portfolio of product offerings focused on surgical and interventional pain management, respiratory and digestive health. Its products include post-operative pain management solutions, minimally invasive interventional or chronic pain therapies, closed airway suction systems and enteral feeding tubes. The company’s products are sold under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, QUIKBLOC, HOMEPUMP, CORTRAK and other brand names.
Company Coordinates stock-summary
Company Details
5405 Windward Parkway , ALPHARETTA GA : 30004
stock-summary
Tel: 1 678 4259273
stock-summary
https://avanos.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."